You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Factors associated with sustained viral response to interferon-alpha therapy

From: High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study

  Total No. Non-SVR† No. (%) SVR† No. (%) P value
Patient Number 200 136(68.0) 64(32.0)  
Gender     NS‡
Male 103 69(70.0) 34(33.0)  
Female 97 67(69.1) 30(30.9)  
Age (year)   47.6 ± 10.0 44.2 ± 13.5 NS
History of transfusion     NS
No 141 97(68.8) 44(31.2)  
Yes 59 39(66.1) 20(33.9)  
Liver histopathology     
   Total score of necroinflammatory activity 4.10 ± 2.59 4.21 ± 2.31 NS
Fibrosis score     <0.01
F3–4 70 57(81.4) 13(18.6)  
F0–2 130 79(60.8) 51(39.2)  
Pretreatment ALT value (IU/L) 87.8 ± 86.5 143.5 ± 153.5 <0.01
Pretreatment serum level of HCV RNA§ 6.17 ± 0.61 5.62 ± 0.56 <0.0001
HCV genotype     
   1b 80 63(78.8) 17(21.3) <0.01
   Non-1b 120 73(60.8) 47(39.2)  
Interferon preparation     NS
   Recombinant IFN-α-2a 37 29(78.4) 8(21.6)  
   Recombinant IFN-α-2b 95 62(65.3) 33(34.7)  
   Lymphoblastoid IFN-α-n1 68 45(66.2) 23(33.8)  
Interferon regimen     <0.05
3-MU group¶ 76 58(76.3) 18(23.7)  
6-MU group¶ 124 78(62.1) 46(37.1)  
  1. † SVR: sustained virological response.
  2. ‡ NS: not significant.
  3. §Presented as log (equivalent/mL).
  4. ¶ 3-MU group: interferon-α 3 million units thrice weekly for 24 weeks; 6-MU group: interferon-α 6 million units thrice weekly for 24 weeks.